Advanced ovarian cancer refers to ovarian cancer that has spread beyond the ovaries and pelvis to other areas of the body. It includes stage III, where the cancer has reached the abdominal lining or lymph nodes, and stage IV, where it has spread to distant organs like the liver or lungs. Most ovarian cancers are diagnosed at an advanced stage because early symptoms are subtle and easy to dismiss.
What Makes Ovarian Cancer “Advanced”
Ovarian cancer is staged using a system developed by the International Federation of Gynecology and Obstetrics (FIGO). Stages I and II are considered early, meaning the cancer is still confined to the ovaries or nearby pelvic structures. Once it moves beyond that boundary, it becomes advanced.
In stage III, the cancer has spread to the abdominal lining (called the peritoneum) outside the pelvis, to lymph nodes in the back of the abdomen, or both. This stage is further divided based on how much visible disease is present. At the lower end, there may only be microscopic deposits on the abdominal lining. At the higher end (stage IIIC), there are visible tumor deposits larger than 2 cm, sometimes extending to the surface of the liver or spleen.
Stage IV means the cancer has reached organs outside the abdomen entirely. Stage IVA involves fluid buildup around the lungs that contains cancer cells. Stage IVB means the cancer has spread into the tissue of distant organs. The most common sites of distant spread are the liver, distant lymph nodes, lungs, bone, and brain, roughly in that order of frequency.
Symptoms of Advanced Disease
Many of the symptoms that finally lead to diagnosis are caused not by the tumor itself but by its effects on surrounding tissue. The hallmark of advanced ovarian cancer is ascites: a buildup of fluid in the abdomen caused by cancer deposits on the abdominal lining. Ascites can make the belly visibly swollen and distended, sometimes rapidly over just a few weeks.
Along with abdominal swelling, common symptoms include shortness of breath, abdominal pain or tenderness, loss of appetite, persistent indigestion, fatigue, constipation, and back pain. These overlap with many benign conditions, which is one reason ovarian cancer often goes unrecognized until it has progressed. When a pelvic mass is found alongside ascites, it is a classic indicator of advanced-stage disease.
How Advanced Ovarian Cancer Is Treated
Treatment for advanced ovarian cancer combines surgery and chemotherapy, but the order depends on the individual situation. The two main approaches are primary debulking surgery followed by chemotherapy, or chemotherapy first (called neoadjuvant chemotherapy) followed by surgery partway through.
The goal of surgery is aggressive: to remove every visible trace of cancer. Over the past decade, the standard has shifted from leaving behind tumor deposits smaller than 1 cm to aiming for no visible residual disease at all. With a specialized gynecologic oncology team, roughly 60 to 70% of patients can reach that benchmark. The less cancer left behind after surgery, the better chemotherapy works afterward.
Not everyone is a candidate for surgery first. Patients over 50, those with significant other health problems, and those with stage IV disease are more likely to receive chemotherapy before surgery. Stage IV patients are nearly three times as likely to start with chemotherapy compared to stage IIIC patients. In this approach, three rounds of chemotherapy shrink the tumor burden, surgery removes what remains, and then three more rounds of chemotherapy follow.
The standard chemotherapy combination is carboplatin paired with paclitaxel, typically given every three weeks. An alternative schedule delivers paclitaxel weekly instead, which some studies suggest improves outcomes. Adding a third drug to this combination has not shown benefit.
Maintenance Therapy After Chemotherapy
One of the biggest advances in recent years is the use of PARP inhibitors as maintenance therapy. These drugs work by blocking a DNA repair pathway that cancer cells rely on, essentially preventing them from fixing damage and causing them to die. They are especially effective in tumors with harmful BRCA1 or BRCA2 gene mutations, which already have faulty DNA repair. About half of high-grade serous ovarian cancers have a broader DNA repair deficiency called homologous recombination deficiency (HRD), and these patients also benefit significantly from PARP inhibitors.
Genetic testing of the tumor is now a routine part of treatment planning. An FDA-approved test can identify whether a tumor is HRD-positive, which helps determine whether maintenance therapy with a PARP inhibitor, sometimes combined with bevacizumab (a drug that blocks blood vessel growth to tumors), is appropriate. For women whose tumors respond to initial chemotherapy and carry these genetic features, maintenance therapy can substantially delay recurrence.
Monitoring and the CA-125 Blood Test
CA-125 is a protein released by ovarian cancer cells and has been the primary blood marker for tracking the disease for four decades. The normal threshold is 35 U/mL. During treatment, rising and falling CA-125 levels predict whether the disease is progressing or responding in about 90% of cases.
After treatment, CA-125 remains a key surveillance tool. A rise to more than double the 35 U/mL threshold is a valid predictor of relapse. Even when levels stay technically within the normal range, three consecutively rising measurements signal a substantially higher risk of recurrence. The test detects recurrent ovarian cancer with a sensitivity of 62 to 94% and specificity of 91 to 100%, making it useful but not perfect. Imaging and symptom monitoring complement it.
Managing Fluid Buildup
Ascites is one of the most physically burdensome aspects of advanced ovarian cancer, and managing it is a major part of care. The primary treatment is paracentesis, a procedure where a needle drains fluid from the abdomen. It provides quick relief from pressure, pain, and shortness of breath, but the fluid often reaccumulates.
For patients who need frequent drainage, a tunneled peritoneal catheter can be placed by an interventional radiologist. This is a small, semi-permanent tube that allows patients and their families to drain fluid at home on a regular schedule, avoiding repeated hospital visits. Effective chemotherapy also helps by reducing the cancer deposits that cause fluid to accumulate in the first place.
Recurrence Rates and Prognosis
Advanced ovarian cancer has a high likelihood of returning after initial treatment. More than 80% of women with advanced-stage disease will experience a recurrence at some point. This is why maintenance therapy and close monitoring are so central to the treatment plan. When cancer does return, doctors reassess after every two to four cycles of treatment to gauge response and adjust the approach.
Five-year relative survival rates provide a broad picture of outcomes. For regional-stage ovarian cancer (roughly corresponding to cancer that has spread within the pelvis and nearby areas), the five-year survival rate is about 79.6%. For distant-stage disease, where cancer has spread to far-off organs, that number drops to 46.6%. These figures, drawn from cases diagnosed between 2015 and 2021, reflect a meaningful improvement over earlier decades, driven largely by better surgical techniques and the introduction of targeted therapies like PARP inhibitors.
Age plays a significant role. Women under 50 with distant-stage disease have a five-year survival rate of about 65%, while those over 65 have a rate closer to 37%. This gap reflects differences in overall health, tolerance for aggressive treatment, and tumor biology.